Kuvan: payments to doctors
Payments that named Kuvan as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $782K
- Providers
- 251
- Transactions
- 1,359
- Average per transaction
- $576
The per-transaction average — $576 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 251 providers the average total is $3,117, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Biomarin Pharmaceutical Inc. | $782,455 | 100.0% |